Human xanthine oxidase recombinant in E. coli: A whole cell catalyst for preparative drug metabolite synthesis

J Biotechnol. 2016 Oct 10:235:3-10. doi: 10.1016/j.jbiotec.2016.03.045. Epub 2016 Mar 25.

Abstract

Human xanthine oxidoreductase (XOR), which is responsible for the final steps of the purine metabolism pathway and involved in oxidative drug metabolism, was successfully expressed in Escherichia coli BL21(DE3) Gold. Recombinant human (rh) XOR yielded higher productivity with the gene sequence optimized for expression in E.coli than with the native gene sequence. Induction of XOR expression with lactose or IPTG resulted in complete loss of activity whereas shake flasks cultures using media rather poor in nutrients resulted in functional XOR expression in the stationary phase. LB medium was used for a 25L fermentation in fed-batch mode, which led to a 5 fold increase of the enzyme productivity when compared to cultivation in shake flasks. Quinazoline was used as a substrate on the semi-preparative scale using an optimized whole cell biotransformation protocol, yielding 73mg of the isolated product, 4-quinazolinone, from 104mg of starting material.

Keywords: Drug metabolites; E. coli; Purine; Whole cell biotransformation; Xanthine oxidase.

Publication types

  • Review

MeSH terms

  • Biotechnology
  • Escherichia coli / genetics*
  • Fermentation
  • Humans
  • Recombinant Proteins* / chemistry
  • Recombinant Proteins* / genetics
  • Recombinant Proteins* / isolation & purification
  • Recombinant Proteins* / metabolism
  • Xanthine Oxidase* / chemistry
  • Xanthine Oxidase* / genetics
  • Xanthine Oxidase* / isolation & purification
  • Xanthine Oxidase* / metabolism

Substances

  • Recombinant Proteins
  • Xanthine Oxidase